Year Founded
2015
Ownership
Public
Employees
~50
Therapeutic Areas
Neurology
Stage
Phase 1
Modalities
Antibody-based immunotherapy

APRINOIA Therapeutics General Information

APNmAb005, a monoclonal antibody targeting tau protein, is in Phase 1 clinical trials for Alzheimer's Disease. Preclinical studies demonstrated its ability to bind tau aggregates, block pathogenic tau transmission, and partially rescue synaptic and neuronal loss.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
,

Drug Pipeline

APNmAb005
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to APRINOIA Therapeutics's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

APRINOIA Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCSep 11, 2023$4.4MCompletedPhase 1
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view APRINOIA Therapeutics's complete valuation and funding history, request access »

APRINOIA Therapeutics Investors

KTB Network (Korea)
Investor Type: Venture Capital
Holding: Minority
DCI Partners (Japan)
Investor Type: Venture Capital
Holding: Minority
ShangPharma Investment Group (China)
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 8 investors. Get the full list »